Eye drop showdown: which lifts droopy eyelids better?
NCT ID NCT07390578
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study compares two FDA-approved eye drops, Upneeq and Lumify, to see which one better lifts droopy eyelids in adults with acquired ptosis. Fifty participants will receive a single drop of each medication on separate visits, and eyelid height will be measured after about an hour. The goal is to find out which drop provides a better temporary lift.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Oxymetazoline 0.1% (Upneeq) and brimonidine 0.025% (Lumify) eye drops
- What this could lead to
- If this trial shows one drop works better, it could help doctors choose the most effective option for temporarily lifting droopy eyelids.
- What could go wrong
- This is a small, early-phase study with only 50 people. The effect is temporary and may not work for everyone. Eye irritation is possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
About 50 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Dec 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adults age ≥18 years * Acquired ptosis with MRD1 ≤ 2.5 mm in at least one eye * Ability to complete both study visits (≥48 hours apart) * Fluent in English * Able to provide informed consent Exclusion Criteria: * Congenital ptosis or mechanical ptosis due to mass effect * Ocular surgery within the past 6 months * Significant active ocular surface disease * Current contact lens wear on study days * Known allergy to oxymetazoline or brimonidine * Use of MAO inhibitors, α-blockers, or contraindicated medications * Pregnancy or lactation * Significant uncontrolled cardiovascular disease * Any condition that may interfere with study procedures or data reliability
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Acquired ptosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.